These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
82. TAILORing targeted therapies to the right patient at the right time: how close are we? Zarkavelis G; Pentheroudakis G Ann Transl Med; 2018 Nov; 6(Suppl 1):S87. PubMed ID: 30613662 [No Abstract] [Full Text] [Related]
83. The Dual Role of Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Two Sides of the Same Coin? Loibl S JAMA Oncol; 2015 Jul; 1(4):455-6. PubMed ID: 26181253 [No Abstract] [Full Text] [Related]
84. Metastatic HER2-Positive Breast Cancer: Tailoring Treatment Un-'TIL' We Get It Right.. Jankowitz RC; Rastogi P Oncology (Williston Park); 2016 Feb; 30(2):156, 158-9. PubMed ID: 26892152 [No Abstract] [Full Text] [Related]
85. Management of Metastatic HER2-Positive Breast Cancer: Where Are We and Where Do We Go From Here? Santa-Maria CA; Nye L; Mutonga MB; Jain S; Gradishar WJ Oncology (Williston Park); 2016 Feb; 30(2):148-55. PubMed ID: 26892151 [TBL] [Abstract][Full Text] [Related]
86. The Evolving Landscape of HER2 Targeting in Breast Cancer. Moasser MM; Krop IE JAMA Oncol; 2015 Nov; 1(8):1154-61. PubMed ID: 26204261 [TBL] [Abstract][Full Text] [Related]
87. Biomarkers for Predicting Response to Anti-HER2 Agents. Varadan V; Sandoval M; Harris LN Adv Exp Med Biol; 2016; 882():155-67. PubMed ID: 26987534 [TBL] [Abstract][Full Text] [Related]
88. A systematic review of dual targeting in HER2-positive breast cancer. Kümler I; Tuxen MK; Nielsen DL Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156 [TBL] [Abstract][Full Text] [Related]
89. Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies. Monteiro Ide P; Madureira P; de Vasconscelos A; Pozza DH; de Mello RA Pharmacogenomics; 2015; 16(3):257-71. PubMed ID: 25712189 [TBL] [Abstract][Full Text] [Related]